Skip to the page

Data / Drug companies / Upsher-Smith Laboratories, LLC

Upsher-Smith Laboratories, LLC: 45 products in the FDA NDC directory, labeler code 0245

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Upsher-Smith Laboratories, LLC (labeler code 0245) lists 45 products in the FDA National Drug Code Directory, covering 15 finished drugs by generic name. By type: 45 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 5, 2026.

The request: Watch Upsher-Smith Laboratories, LLC (FDA labeler code 0245): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
0245
Products in commercial distribution
45
Packages
90
Finished drugs by generic name
15
Prescription products
45
Over the counter products
0
Controlled substance products
Schedule II 3, Schedule III 2
Flagged as original packager
43 of 43 products that carry the flag
Started marketing in the last 12 months
1
Products with a marketing end date set
4
Earliest marketing start
April 17, 1986
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)3168.9%
New drug applications (NDA)1328.9%
Other unapproved drugs12.2%

Products by type

TypeProductsShare
Prescription drugs45100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet2044.4%
Capsule, extended release511.1%
Tablet, film coated, extended release48.9%
Capsule, liquid filled48.9%
Tablet, extended release36.7%
Gel24.4%
Powder, for solution24.4%
Powder, for suspension12.2%
Spray12.2%
Suspension12.2%
Gel, metered12.2%
Tablet, effervescent12.2%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Kymbee0245-0813SuspensionGeneric drugs (ANDA)June 5, 2026
Klor-con0245-0836Tablet, film coated, extended releaseGeneric drugs (ANDA)August 15, 2025
Klor-con0245-0835Tablet, film coated, extended releaseGeneric drugs (ANDA)August 15, 2025
Kymbee0245-0817TabletGeneric drugs (ANDA)November 5, 2024
Kymbee0245-0816TabletGeneric drugs (ANDA)November 5, 2024
Kymbee0245-0815TabletGeneric drugs (ANDA)November 5, 2024
Kymbee0245-0814TabletGeneric drugs (ANDA)November 5, 2024
Vigadrone0245-6001TabletGeneric drugs (ANDA)June 29, 2023
Torpenz0245-0825TabletGeneric drugs (ANDA)October 1, 2021
Torpenz0245-0824TabletGeneric drugs (ANDA)October 1, 2021
Torpenz0245-0823TabletGeneric drugs (ANDA)October 1, 2021
Torpenz0245-0822TabletGeneric drugs (ANDA)October 1, 2021
Isotretinoin0245-0573Capsule, liquid filledGeneric drugs (ANDA)September 21, 2021
Isotretinoin0245-0571Capsule, liquid filledGeneric drugs (ANDA)September 21, 2021
Isotretinoin0245-0570Capsule, liquid filledGeneric drugs (ANDA)September 21, 2021
Isotretinoin0245-0575Capsule, liquid filledGeneric drugs (ANDA)April 12, 2021
Pacerone0245-1645TabletGeneric drugs (ANDA)July 2, 2020
Tosymra0245-0812SprayNew drug applications (NDA)July 8, 2019
Vigadrone0245-0556Powder, for solutionGeneric drugs (ANDA)June 21, 2018
Klor-con0245-0360Powder, for solutionGeneric drugs (ANDA)October 23, 2017
Hydrocodone Bitartrate and Acetaminophen0245-0412TabletGeneric drugs (ANDA)March 27, 2017
Hydrocodone Bitartrate and Acetaminophen0245-0411TabletGeneric drugs (ANDA)March 27, 2017
Hydrocodone Bitartrate and Acetaminophen0245-0410TabletGeneric drugs (ANDA)March 27, 2017
KLOR-Con/EF0245-5326Tablet, effervescentOther unapproved drugsSeptember 1, 2014
Vogelxo0245-0872Gel, meteredNew drug applications (NDA)June 9, 2014

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.